Novartis oncology drug bolsters revenue with another EU approval

By Dani Bancroft contact

- Last updated on GMT


Related tags: European union

The European Commission has approved oral formulation of Novartis' seizure treatment Everolimus under the trade name Votubia.

Votubia was cleared as a combination therapy for patients aged two and up who experience refractory partial-onset seizures associated to tuberous sclerosis complex (TSC).

These kind of seizures are caused by growth of non-cancerous lesions in the brain in TSC, and affect up to 60% of patients the rare genetic disease.

Everolimus is a small molecule inhibitor of mTOR – the mammalian target of rapamycin which regulates cell division and metabolism – to prevent the tumors from forming.

The drug is already marketed by Novartis under the names Zortress (US) and Certican (EU) as an immunosuppressant for transplant surgery, and as Afinitor to treat general tumours.

Novartis claims Votubia is the only non-surgical treatment for TSC related seizures to be available in all 28 EU member states. It is also available in Iceland and Norway.

Increase in sales

Previously Novartis has told in-PharmaTechnologist it plans to expand the indication portfolio for Everolimus, after the firm said it had projected sales for the drug to take a hit​ with competition from Bristol-Myers Squibb’s Opdivo.

However, despite Novartis expecting a slow in sales for the biologic, total annual revenues for Everolimus in 2016 exceeded $390 million - up 19% compared to FY2015​.

Votubia tablets and dispersible tablets are also indicated in the EU for the treatment of patients with subependymal giant cell astrocytoma (SEGA) linked to TSC.

Related news

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us


View more